News

  • 22 February 2018

    4Tech Inc., a leader in the field of transcatheter tricuspid valve repair, announces changes in its leadership team: Tom Fleming will join the company as President and Chief Executive Officer (CEO), effective as of March 2018; and Keith D. Dawkins, M.D., has joined as Chief Medical Officer (CMO), effective immediately. Tom Fleming replaces Mike Ennen, who is stepping down for family reasons. This new leadership team enhances the company's strategy to advance its clinical program for TriCinch™ Coil System. 

  • 20 February 2018

    Axonics Modulation Technologies, Inc. announced today that three clinical articles relating to its miniaturized, rechargeable Sacral Neuromodulation system (Axonics r-SNM™ System) have been published in a special edition of the Journal of Neurourology and Urodynamics (NUU).

  • 20 February 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in a preclinical model showed that GKT831, the Company’s NOX1 and NOX4 inhibitor, efficiently targeted cancer associated fibroblasts (CAFs) in prostate cancer and abrogated the pro-tumorigenic influence of the tumor micro-environment. The results of this study, which was conducted by Dr. Natalie Sampson and colleagues at the Medical University of Innsbruck, were published in the International Journal of Cancer (https://doi.org/10.1002/ijc.31316).

  • 16 February 2018

    Wilson Therapeutics (publ) today announced that the first patient has been enrolled in the pivotal Phase 3 FOCuS clinical trial evaluating WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent with a unique mechanism of action, for the treatment of Wilson Disease. FOCuS is a randomized, controlled, rater-blinded, multi-center study that will enroll approximately 100 Wilson Disease patients, aged 18 years or over, to receive once-daily WTX101 or standard of care. The primary endpoint will be copper control assessed as the percentage change in free copper levels in blood from baseline to 48 weeks. Top-line data from the study is expected to be released H2 2019.

  • 14 February 2018

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s first-in-human, Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch. SNA-125 is designed to inhibit janus kinase 3, or JAK3, and tropomyosin receptor kinase A, or TrkA, with minimal to no systemic exposure. JAK3 is a validated target in psoriasis, atopic dermatitis and pruritus. JAK3 is required for immune cell development, and inhibiting JAK3 blocks the signaling of key cytokines, such as interleukin-17A, or IL-17A, IL-17F, IL-2 and tumor necrosis factor-alpha, or TNF-α, which results in a reduction in the severity of autoimmune and inflammatory diseases in which those cytokines play a pivotal role. TrkA is the high affinity receptor for nerve growth factor, or NGF, a known mediator of neurogenic inflammation and itch associated with psoriasis. This multicenter, randomized, double-blind, placebo- and comparator-controlled, intra-individual trial will evaluate the safety, tolerability and efficacy of SNA-125 compared to vehicle and other reference formulations in approximately 15 patients with chronic psoriasis.